Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...

The FDA will lose about 3,500 employees under the plans, although HHS said drug, medical device and food reviewers will not ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...